BeiGene
BGNE
#934
Rank
โ‚ฌ19.96 B
Marketcap
179,48ย โ‚ฌ
Share price
-2.10%
Change (1 day)
-0.87%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of June 2024 : โ‚ฌ5.41 Billion

According to BeiGene 's latest financial reports the company's total assets are โ‚ฌ5.41 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31โ‚ฌ5.25 B-11.7%
2022-12-31โ‚ฌ5.94 B-21.09%
2021-12-31โ‚ฌ7.53 B65.52%
2020-12-31โ‚ฌ4.55 B216.38%
2019-12-31โ‚ฌ1.43 B-26.81%
2018-12-31โ‚ฌ1.96 B125.47%
2017-12-31โ‚ฌ0.87 B126.06%
2016-12-31โ‚ฌ0.38 B261.28%
2015-12-31โ‚ฌ0.10 B142.22%
2014-12-31โ‚ฌ44.08 M416.08%
2013-12-31โ‚ฌ8.54 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
โ‚ฌ17.23 M-99.68%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ1.87 B-65.34%๐Ÿ‡บ๐Ÿ‡ธ USA